MedTrace Logo

Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

NCT00939965 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors plan better treatment for patients receiving isotretinoin.

PURPOSE: This clinical trial is studying the side effects and best dose of isotretinoin in treating young patients with high-risk neuroblastoma.

Conditions

Interventions

DRUG

isotretinoin

GENETIC

DNA analysis

GENETIC

polymerase chain reaction

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    lead OTHER

Principal Investigators

  • Gareth Veal · University of Newcastle Upon-Tyne

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00939965 on ClinicalTrials.gov